Genomics in Drug Discovery and Development / Edition 1

Hardcover (Print)
Buy New
Buy New from
Used and New from Other Sellers
Used and New from Other Sellers
from $115.78
Usually ships in 1-2 business days
(Save 22%)
Other sellers (Hardcover)
  • All (9) from $115.78   
  • New (8) from $115.78   
  • Used (1) from $133.64   


Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
Read More Show Less

Editorial Reviews

From The Critics
Reviewer: Steven N. Hart, BS (University of Kansas Medical Center)
Description: This book is a start-to-finish approach to incorporating genomic data into the drug discovery pipeline.
Purpose: The purpose is to introduce many novel strategies, technologies, and toolboxes to aid researchers and industry professionals in progressing toward personalized medicine. More specifically, this book addresses three major components essential for personalized medicine: biomarker discovery, toxicogenomics, and pharmacogenomics with a particular emphasis on incorporating these platforms during early stages of drug design. The rationale for this approach is to stratify patient populations to identify subjects at risk of clinically significant toxicity and nonresponders to allow for safer, more effective, and more rapid drug discovery. These objectives are well defined and clearly addressed.
Audience: The book is intended to be of interest to academics, biologists in the pharmaceutical industry, and regulatory personnel who are in a position to appreciate the complexity of genomics and the wealth of useful information that it can provide. The idea is that these professionals will incorporate genomic data mining into drug discovery platforms. Many topics in this book will be of particular interest and familiarity to only one of these subgroups at a time, whereas those inexperienced in a particular area may find themselves being introduced to new concepts, but in a clear, easy to follow manner.
Features: In the book's nine chapters, readers are exposed to all relevant aspects of the strategies for and the implications of genomics in drug discovery and development. There is a strong and necessary emphasis on toxicogenomics, which serves as a major bottleneck in the drug development pipeline. Among others topics, gene expression array technology, data analysis, and how to make data publicly accessible in genomics databases - a requirement for all government funded genomics studies - are thoroughly covered.
Assessment: This book covers many of the relevant aspects of incorporating genomics into the standard drug discovery workflow. Of particular interest to me was the chapter on genomics technologies as tools in drug discovery. As an academic involved in genomics and pharmacology, I use many of the tools in this book frequently. The authors address many of the pitfalls associated with these technologies and also identify several key computational biology tools (such as databases) essential for the interpretation of genomics in drug discovery. The book also introduced me to the regulatory implications of how to transition genomics from the bench to bedside, a viewpoint that is sometimes lost in academia. Overall, it provides excellent, up-to-date coverage of the application of genomics in drug development.
Read More Show Less

Product Details

  • ISBN-13: 9780470096048
  • Publisher: Wiley, John & Sons, Incorporated
  • Publication date: 11/10/2008
  • Edition number: 1
  • Pages: 496
  • Product dimensions: 6.30 (w) x 9.30 (h) x 1.10 (d)

Meet the Author

Dimitri Semizarov, PhD, is a Senior Group Leader in the Cancer Research Department of Abbott Laboratories' Global Pharmaceutical R&D. Dr. Semizarov leads cancer genomics research at Abbott, applying genomics technologies to enable personalization of cancer therapy. He is author or coauthor of more than twenty scientific articles and eight patent applications, as well as three book chapters (including two chapters in Wiley's Preclinical Development Handbook).

Eric Blomme, DVM, PhD, Diplomate, American College of Veterinary Pathologists, is a Senior Project Leader for Cellular, Molecular, and Exploratory Toxicology in Global Pharmaceutical R&D at Abbott Laboratories. He has extensive drug discovery, toxicology, and screening experience working for Abbott, Pharmacia, Monsanto, Searle, Ohio State University, and Cornell University. Dr. Blomme has written over fifty journal articles and eight book chapters, and is a reviewer for multiple scientific journals in the fields of toxicology and pathology.

Read More Show Less

Table of Contents


Chapter 1: Introduction: Genomics and Personalized Medicine (Dimitri Semizarov).

1.1. Fundamentals of genomics.

1.2. The concept of personalized medicine.

1.3. Genomics technologies in drug discovery.

1.4. Scope of this book.


Chapter 2: Genomics Technologies as Tools in Drug Discovery (Dimitri Semizarov).

2.1. Introduction to genomics technologies.

2.2. Gene expression microarrays: technology.

2.2.1. Standard microarray protocol.

2.2.2. Monitoring the quality of RNA for microarray experiments.

2.2.3. Specialized microarray protocols for archived and small samples.

2.2.4. Quality of microarray data and technical parameters of microarrays.

2.2.5. Reproducibility of expression microarrays and cross-platform comparisons.

2.2.6. Microarray databases and annotation of microarray data.

2.3. Gene expression microarrays: data analysis.

2.3.1. Identification of significant gene expression changes.

2.3.2. Sample classification and class prediction using expression microarrays.

2.3.3. Pathway analysis with gene expression microarrays.

2.3.4. Common problems affecting the validity of microarray studies.

2.4. Comparative genomic hybridization: technology.

2.5. Comparative genomic hybridization: data analysis.

2.6. Microarray-based DNA methylation profiling.

2.7. Microarray-based microRNA profiling.

2.8. Technical issues in genomics experiments and regulatory submissions of microarray data.

2.8.1. Study of a drug’s mechanism of action by gene expression profiling.

2.8.2. Early assessment of drug toxicity in model systems.

2.8.3. Biomarker identification in discovery and early development.

2.8.4. Patient stratification in clinical trials using gene expression signatures.

2.8.5. Genotyping of patients in clinical studies to predict drug response.

2.9. Conclusion.


Chapter 3: Genomic Biomarkers (Dimitri Semizarov).

3.1. Introduction into genomic biomarkers.

3.2. DNA biomarkers.

3.2.1. DNA copy number alterations. DNA copy alterations in cancer. DNA copy number alterations in other diseases. Identification of DNA copy number biomarkers in drug discovery.

3.2.2. Mutations. p53 mutations. K-ras mutations. EGFR mutations. Bcr-abl and KIT mutations.

3.2.3. Epigenetic markers.

3.3. RNA biomarkers.

3.3.1. Gene expression biomarkers validated as diagnostic tests.

3.3.2. Other examples of gene expression biomarkers.

3.4. Clinical validation of genomic biomarkers.


Chapter 4: Fundamental Principles of Toxicogenomics (Eric Blomme).

4.1. Introduction.

4.2. Fundamentals of toxicogenomics.

4.2.1. Principle of toxicogenomics.

4.2.2. Technical reproducibility.

4.2.3. Biological reproducibility.

4.2.4. Species extrapolation.

4.3. Analysis of toxicogenomics data.

4.3.1. Compound-induced gene expression changes.

4.3.2. Visualization tools.

4.3.3. Class prediction.

4.3.4. Network and pathway analysis.

4.4. Practical and logistic aspects of toxicogenomics.

4.4.1. Species considerations.

4.4.2. Toxicogenomics studies. Sample considerations. Experimental design in toxicogenomics studies.

4.5. Toxicogenomics reference databases.

4.5.1. The utility of reference databases in toxicogenomics.

4.5.2. Design and development of toxicogenomics reference databases.

4.5.3. Existing toxicogenomics databases.

4.6. Conclusion.


Chapter 5: Toxicogenomics: Applications to In Vivo Toxicology (Eric Blomme).

5.1. The value of toxicogenomics in drug discovery and development.

5.2. Basic principles of toxicology in drug discovery and development.

5.2.1. Preclinical safety assessment.

5.2.2. Discovery toxicology.

5.3. Toxicogenomics in predictive toxicology.

5.3.1. Prediction of hepatotoxicity.

5.3.2. Prediction of nephrotoxicity.

5.3.3. Prediction of in vivo carcinogenicity.

5.3.4. Gene expression-based biomarkers in other tissues and the promise of hemogenomics.

5.3.5. Integration of toxicogenomics in discovery toxicogology.

5.4. Toxicogenomics in mechanistic toxicology.

5.4.1. Toxicogenomics to investigate mechanisms of hepatotoxicity.

5.4.2. Intestinal toxicity and Notch signaling.

5.4.3. Cardiac toxicity.

5.4.4. Testicular toxicity.

5.5. Toxicogenomics and target-related toxicity.

5.5.1. Target expression in normal tissues.

5.5.2. Target modulation.

5.6. Predicting species-specific toxicity.

5.7. Evaluation of idiosyncratic toxicity with toxicogenomics.

5.8. Conclusion.


Chapter 6: Toxicogenomics: Applications in In Vitro Systems (Eric Blomme).

6.1. Introductory remarks on in vitro toxicology.

6.2. Overview of the current approaches to in vitro toxicology.

6.3. Toxicogenomics in in vitro systems: technical considerations.

6.3.1. Reproducibility.

6.3.2. Genomic classifiers.

6.3.3. Testing concentrations.

6.3.4. Throughput and cost.

6.4. Proof-of-concept studies using primary rat hepatocytes.

6.5. Use of gene expression profiling to assess genotoxicity.

6.5.1. Toxicogenomics can differentiate genotoxic carcinogens from non-genotoxic carcinogens.

6.5.2. Toxicogenomics can differentiate DNA reactive from non-DNA reactive compounds positive in the in vitro mammalian cell-based genotoxicity assays.

6.5.3. Toxicogenomics assays may be less sensitive than the standard battery of in vitro genetic toxicity tests.

6.6. Application of gene expression profiling for the in vitro detection of phopholipidosis.

6.7. Toxicogenomics in the assessment of idiosyncratic hepatotoxicity.

6.8. Do peripheral blood mononuclear cells represent a useful alternative in vitro model?

6.9. Current and future use of in vitro toxicogenomics.

6.9.1 Improved gene expression platforms.

6.9.2. Standardization of protocols and experimental approaches.

6.9.3. Performance accuracy.

6.9.4. Battery of gene expression signatures.

6.9.5. Clear actionable data points.

6.10. Conclusion.


Chapter 7: Germ Line Polymorphisms and Drug Response (Dimitri Semizarov).

7.1. Introduction into germline polymorphisms.

7.2. Polymorphisms and drug response in oncology.

7.2.1. UGT1A1 polymorphism and response to irinotecan.

7.2.2. FGFR4 polymorphism and response to chemotherapy.

7.2.3. Mdr-1 polymorphism and response to paclitaxel.

7.2.4. DPD polymorphisms and response to 5’-fluorouracil.

7.2.5. TPMT variants and response to thiopurines.

7.2.6. MTHFR polymorphisms and response to chemotherapy.

7.2.7. Tandem repeat polymorphisms in the TS gene and response to drugs targeting thymidylate synthase.

7.2.8. Use of cancer cell lines to identify predictive SNPs.

7.3. Polymorphisms and response to anticoagulants.

7.4. Polymorphisms in neuroscience.

7.5. Polymorphisms and drug response in immunology.

7.6. Polymorphisms and response to antiviral agents.

7.6.1. Anti-HIV drugs.

7.6.2. Interferon therapy in hepatitis B treatment.

7.7. Gene copy number polymorphisms.

7.8. Conclusions: approaches to identification of polymorphisms as predictors of drug response.

7.8.1. Candidate gene approach.

7.8.2. Genome-wide approach.

7.8.3. Pathway approach.

7.8.4. Use of model systems in the identification of predictive pharmacogenetic markers.

7.8.5. Comparison of the methodologies in the context of drug discovery.


Chapter 8: Pharmacogenetics of Drug Disposition (Anahita Bhathena).

8.1. Introduction.

8.2. Genes and polymorphisms affecting drug disposition.

8.2.1. Drug metabolizing enzymes.

8.2.2. Drug transport proteins.

8.3. Genomic biomarkers for PK studies.

8.4. Utility of PG--PK studies in early clinical trials.

8.5. Limitations of PG--PK studies.

8.6. Genotyping technologies.

8.7. Conclusion.


Chapter 9: Overview of Regulatory Developments and Initiatives Related to the Use of Genomic Technologies in Drug Discovery and Development (Eric Blomme).

9.1. Introduction into recent regulatory developments in the genomic area.

9.2. FDA guidance on pharmacogenomic data submission.

9.2.1. Voluntary genomic data submission (VGDS).

9.2.2. Pharmacogenomic data submission.

9.2.3. International harmonization.

9.3. Pharmacogenomic data submission: draft companion guidance.

9.4. Drug-diagnostic co-development concept paper.

9.5. Regulations for in vitro diagnostic assays.

9.5.1. General overview of regulatory pathways for devices in the U.S.A.

9.5.2. Draft guidance for industry, clinical laboratories, and FDA staff on in vitro diagnostic multivariate index assays.

9.6. Biomarker qualification.

9.7. Current initiatives relevant to pharmacogenomics.

9.8. Future impact of genomic data on drug development.



Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Terms of Use.
  • - Barnes & reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)